Skip to content

BioNTech SE Price, Chart & Factor Exposure

Free Data & Analytics Access

Latest earnings: November 3, 2026 results vs estimates

BioNTech SE · E.BNTX.NASDAQ · United States
Use symbol E.BNTX.NASDAQ in our API & Excel add-in to retrieve this data ↓
89.13
(+0.01%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum -100%
Trend -100%
Bubble Risk LOW
Realised Volatility (20D) 40.39%

BioNTech SE Forecast

BioNTech SE short-term momentum is strongly negative (up over 0 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term SELL signal. The long-term trend is strongly negative (0 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term SELL signal. Based on 20-day realised volatility of 40.4% a year, a typical one-standard-deviation range is 84.06–94.20 over a week, 78.74–99.52 over a month and 53.13–125.13 over a year. (Signals as of 1 Nov 2026.)

BioNTech SE Price Chart

MacroFinance.ai
Market/MacroIndicatorNowChangeRange
Quantitative
BioNTech SE
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
BioNTech SE
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
BioNTech SE
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
BioNTech SE
P/S
9.34x
Stretched vs own history
QoQ −16.4%
YoY +28.8%
now 9.34237.02 low11.17 high
ⓘP/S As of 22 Nov 2026.See BioNTech SE returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
BioNTech SE
P/B
1.27x
Mid-range vs own history
QoQ −23.5%
YoY +2.9%
now 1.27321.09 low1.66 high
ⓘP/B As of 22 Nov 2026.See BioNTech SE returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
BioNTech SE
EV/Sales
5.27x
Stretched vs own history
QoQ −30.8%
YoY +93.5%
now 5.26522.25 low7.61 high
ⓘEV/Sales As of 22 Nov 2026.See BioNTech SE returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
BioNTech SE
FCF Yield
-2.0%
Mid-range vs own history
QoQ −215.3%
YoY −72.8%
now -2.023-7.68 low2.33 high
ⓘFCF Yield As of 22 Nov 2026.See BioNTech SE returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
BioNTech SE
Earnings Yield
-6.6%
Weak vs own history
QoQ +14.5%
YoY +162.3%
now -6.5592-7.62 low-2.06 high
ⓘEarnings Yield As of 22 Nov 2026.See BioNTech SE returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
BioNTech SE
Market Cap
$22.5B
Mid-range vs own history
QoQ −23.6%
YoY −1.4%
now 22549.8920,483 low29,531 high
ⓘMarket Cap As of 22 Nov 2026.See BioNTech SE returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
BioNTech SE
Net Debt
-$9.8B
Mid-range vs own history
QoQ +4.5%
YoY −31.1%
now -9841-14,567 low-9,421 high
ⓘNet Debt As of 22 Nov 2026.See BioNTech SE returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
BioNTech SE
Current Ratio
8.55x
Mid-range vs own history
QoQ +9.0%
YoY +20.1%
now 8.55187.12 low8.8 high
ⓘCurrent Ratio As of 22 Nov 2026.See BioNTech SE returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
BioNTech SE
Quick Ratio
8.52x
Mid-range vs own history
QoQ +9.2%
YoY +21.3%
now 8.51647.02 low8.74 high
ⓘQuick Ratio As of 22 Nov 2026.See BioNTech SE returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
BioNTech SE
Interest Coverage
-52.90x
Weak vs own history
QoQ −38.5%
YoY +88.2%
now -52.9007-86.04 low-28.11 high
ⓘInterest Coverage As of 22 Nov 2026.See BioNTech SE returns when Interest Coverage looked like now →Opens Return analysis with the filter Interest Coverage within ±5% of today
BioNTech SE
Debt / Equity
0.02x
High vs own history
QoQ +14.0%
YoY +52.8%
now 0.02030.01 low0.02 high
ⓘDebt / Equity As of 22 Nov 2026.See BioNTech SE returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
BioNTech SE
Piotroski F-Score
2
Weak vs own history
QoQ 0.0%
YoY −33.3%
now 22 low4 high
ⓘPiotroski F-Score As of 22 Nov 2026.See BioNTech SE returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
BioNTech SE
Altman Z-Score
7.37
Mid-range vs own history
QoQ −14.8%
YoY +8.0%
now 7.37266.45 low8.65 high
ⓘAltman Z-Score As of 22 Nov 2026.See BioNTech SE returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  18 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  21 members-only factors: Sloan Accruals, Cash-Earnings Gap, Beneish M-Score, Days Sales in Receivables Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for BioNTech SE, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

BioNTech SE fundamentals: income statement, balance sheet & cash flow

BioNTech SE reported revenue of $2.76bn and net income of -$1.09bn in FY2025, the year ended 31 December 2025 — revenue up 0.2% and net income down 64.0% on the prior year. Free cash flow was $269.8m. These figures are as reported in the filings, not restated: 9 fiscal years and 35 quarters of history, back to December 2017. 165 FINRA short-interest settlements are published alongside them, back to October 2019.

Revenue (FY2025)
$2.76bn
+0.2%
Net income
-$1.09bn
-64.0%
Gross margin
77.64%
Free cash flow
$269.8m
+210.3%
Net debt
-$7.40bn
Shares short (30 Oct 2026)
2.25m
2.15 days to cover
BioNTech SE income statement, annual, as reported · USD billions unless stated
USD billionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue2.762.753.8217.3118.98
Cost of revenue0.620.540.603.002.91
Gross profit2.142.213.2214.3216.07
Research & development2.022.251.781.540.95
Selling, general & admin.—1.27—0.14—
Operating income-0.62-1.310.6912.6415.28
EBITDA-0.63-0.371.3813.1015.00
Interest expense0.010.010.010.020.01
Pre-tax income-1.01-0.681.1912.9515.05
Income tax0.08-0.010.263.524.75
Net income-1.09-0.670.939.4310.29

Download BioNTech SE fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.BNTX.NASDAQ&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks the full history, the filing vintages behind each number and API access.
Create free account

Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.

Research on BioNTech SE

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

BioNTech SE Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to BioNTech SE; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

Statistical Distribution of Returns

Plus

How BioNTech SE’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how BioNTech SE behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About BioNTech SE (United States)

BioNTech SE is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

Frequently asked questions

What is BioNTech SE?
BioNTech SE is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest BioNTech SE price?
The latest close is 89.13 (1 Nov 2026), +0.01% on the day. The price at the top of the page refreshes during the trading day.
Is BioNTech SE in an uptrend?
As of 1 Nov 2026, short-term momentum is strongly negative (0 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly negative (0 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is BioNTech SE?
20-day realised volatility is 40.4% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 11.7% over a month and 5.7% over a week.
What factors affect BioNTech SE?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to BioNTech SE, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade BioNTech SE?
58 backtested tactical asset allocation strategies trade BioNTech SE through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are BioNTech SE returns analysed?
The Statistical Distribution of Returns section shows the distribution of BioNTech SE daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free BioNTech SE historical data?
In the Free historical data section of this page: the last 10 years of BioNTech SE daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free BioNTech SE historical data (last 10 years)

Browse or instantly download the last 10 years of BioNTech SE daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.BNTX.NASDAQ&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-2080.96
2026-11-1981.38
2026-11-1883.26
2026-11-1784.86
2026-11-1685.26
2026-11-1385.6
2026-11-1285.04
2026-11-1187.65
2026-11-1087.21
2026-11-0987.51
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.